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Abstract
Background: The major histocompatibility complex class II transactivator (CIITA) regulates MHC class II gene
expression. A promoter SNP -168A®G (rs3087456) has previously been shown to be associated with susceptibility
to several immune mediated disorders, including rheumatoid arthritis (RA), multiple sclerosis (MS) and myocardial
infarction (MI). Myasthenia gravis (MG) is an autoimmune disorder which has previously been shown to be
associated with polymorphisms of several autoimmune predisposing genes, including IL-1, PTPN22, TNF-a and the
MHC. In order to determine if allelic variants of rs3087456 increase predisposition to MG, we analyzed this SNP in
our Swedish cohort of 446 MG patients and 1866 controls.
Results: No significant association of the SNP with MG was detected, neither in the patient group as a whole, nor
in any clinical subgroup. The vast majority of previous replication studies have also not found an association of the
SNP with autoimmune disorders.
Conclusions: We thus conclude that previous findings with regard to the role of the CIITA -168A®G SNP in
autoimmunity may have to be reconsidered.
Background
Myasthenia gravis (MG) is an antibody mediated auto-
immune disorder characterized by auto-antibodies
against the nicotinic acetylcholine receptor situated on
the muscle end-plate. These auto-antibodies impair the
transmission of nerve impulses to the muscle. MG
patients commonly display thymic abnormalities such as
hyperplasia and thymoma and the latter is usually asso-
ciated with severe disease. MG occurs in 14.1 per
100,000 persons in Sweden, and has a concordance rate
of 30-40% in monozygotic twins and 2-3% in dizygotic
twins, indicating a strong genetic component. Subgroups
of patients have commonly been made based on age of
onset, thymic status, and disease severity. Several auto-
immune predisposing genes have previously been shown
to be associated with MG, including IL-1, PTPN22, and
genes in the major histocompatibility complex (MHC),
particularly the human leukocyte antigen (HLA)-B8,
DR3 haplotype and TNF-a [1].
The class II transactivator (CIITA, GenBank accession
number NM_000246), located on chromosome 16p13, is
a transactivator of the MHC class II genes [2]. Four
alternative promoters, which exhibit cell-type-specific
activity, drive transcription of the CIITA gene [3].
Expression of MHC class II proteins is crucial for cell
collaboration and induction of immune responses, and
lack of expression is associated with the severe immuno-
deficiency disease bare lymphocyte syndrome (BLS) [2].
In view of its suggested role in autoimmune disorders
[4], we sought to determine if the CIITA rs3087456 var-
iant is associated with autoimmune MG, using a large
cohort of Swedish patients.
Methods
Patients and controls
This study included 466 unrelated Swedish MG patients
and 1866 healthy control individuals of self-reported
European ancestry. MG was diagnosed as described pre-
viously [5], and clinical information was documented by
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the primary physician. The controls were derived from
blood donors in the Stockholm area (n = 533; adults)
and from a population based Swedish material (n =
1333; newborns) [6]. Ethical permission was obtained
from the Karolinska Institutet for use of patient and
control samples.
MHC2TA genotyping
Genotyping of the 446 MG cases and 1866 control sam-
ples was performed using matrix-assisted laser deso-
rption/ionization time-of-flight (MALDI-TOF) [7] mass
spectrometry (SEQUENOM Inc., San Diego, California,
USA) at the Mutation Analysis Facility of the Karolinska
Institutet, Sweden. PCR was conducted using forward
primer ACGTTGGATGCTTCACCAAATTCAGTCCAC
and reverse primer ACGTTGGATGTTTACCA-
CACTCCCTTAAGC. The MHC SNP rs3087456 was
genotyped using iPLEX chemistry utilizing unextended
primer (UEP) CACTCCCTTAAGCCCTCCC and exten-
sion primers CACTCCCTTAAGCCCTCCCC and
CACTCCCTTAAGCCCTCCCT.
Statistical analysis
The c2 test was used to compare genotypes and allele
frequencies of the CIITA SNP in patients and controls.
For the overall MG cohort, a p-value below 0.05 was
considered to indicate statistical significance. For subse-
quent analyses, a Bonferroni correction was applied
based on the number of subgroups to determine the sig-
nificance threshold. Power for the study was calculated
using “CaTS - Power Calculator for Two Stage Associa-
tion Studies” (http://www.sph.umich.edu/csg/abecasis/
CaTS/) [8]. The study had 80% power to detect allelic
odds ratios greater than 1.28 at the stated significance
level (a = 0.05), with a MAF of 0.266 using an additive
model and 1.39 using a dominant model.
Patient subgrouping
Due to the complex nature of MG, we stratified the
patient material into subgroups based on clinical infor-
mation to investigate association to potential sub-
classes of the disease. Patients were thus separated on
the basis of thymic histopathology identified post-
operatively after thymectomy (not operated, normal,
hyperplasia or thymoma), disease severity (ocular, gen-
eralized or severe) and by age of onset. A Bonferroni
correction for the eight subgroups created was applied
to the significance threshold (p < 6.25 × 10-3) used in
subsequent comparisons.
There is a lack of consensus regarding the age which
most accurately separates early onset MG (EOMG) from
late onset MG (LOMG), with several publications using
50 years of age [9,10] and others using 40 years of age
[11]. Therefore, in order to avoid erroneous results,
patients with an age of disease onset less than 40 years
constituted the EOMG group, while those with age of
onset of 50 years or older were included in the LOMG
group.
Results
There were no significant differences in the rs3087456
allele frequency between the blood donor (n = 533;
adults) and population based (n = 1333; newborns) con-
trol subgroups (p = 0.192). Therefore, they were pooled
into one group comprising 1866 samples.
The genotyping results for the 446 MG patients and
1866 controls and p-values of association of the SNP
with MG are given in Table 1. No statistically significant
difference was observed between MG patients and con-
trols for either allele frequencies (p = 0.092) or geno-
types (p = 0.251). The strongest associations were in the
ocular and EOMG subgroups, with uncorrected p-values
of 0.040 and 0.010, respectively. Nevertheless, they
Table 1 Results of CIITA genotyping in MG patients and controls
MG patients AA AG GG A G MAF p-vala Significance threshold OR (95% C.I.) p-val referenceb
All patients (n = 446) 260 159 27 679 213 0.239 0.092 0.05 0.86 (0.73-1.02) 0.154
Age of onset <40 (n = 226) 127 80 19 334 118 0.261 0.810 6.25 × 10-3 1.03 (0.82-1.28) 0.032
Age of onset >50 (n = 175) 110 59 6 279 71 0.203 0.010 6.25 × 10-3 1.43 (1.09-1.87) 0.559
Ocular (n = 42) 29 12 1 70 14 0.167 0.040 6.25 × 10-3 0.55 (0.31-0.98) 0.274
Generalized (n = 404) 231 147 26 609 199 0.246 0.240 6.25 × 10-3 0.90 (0.76-1.07) 0.068
Not operated (n = 171) 103 58 10 264 78 0.228 0.124 6.25 × 10-3 0.81 (0.63-1.06) 0.619
Normal thymus (n = 60) 35 25 0 95 25 0.208 0.156 6.25 × 10-3 0.72 (0.46-1.13) 0.833
Thymic hyperplasia (n = 157) 87 59 11 233 81 0.258 0.747 6.25 × 10-3 0.96 (0.74-1.25) 0.090
Thymoma (n = 58) 35 17 6 87 29 0.250 0.695 6.25 × 10-3 0.92 (0.60-1.41) 0.389
aControls (n = 1866) 1015 708 143 2738 994 0.266
bControls (n = 1599) 989 528 82 2506 692 0.216
Genotypes, frequencies of A and G alleles as well as the minor allele frequency (MAF) for MG patients and various subgroups of patients compared to the
measured controlsa and the controls from Swanberg et. al.b [4]. The significance threshold applies a Bonferroni correction for eight tests on subsequent subgroup
classifications.
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yielded non-significant p-values when compared with
the corrected significance threshold of 6.25 × 10-3.
Discussion
Previously, evidence for association between the CIITA
type III promoter (-168A/G, rs3087456) and rheuma-
toid arthritis (RA) and multiple sclerosis (MS) was
reported [4]. This polymorphism is associated with
reduced transcription levels of CIITA ex vivo in human
leukocytes stimulated with interferon-g, and in vivo
experiments in rats have demonstrated a strong corre-
lation between lowered levels of CIITA transcripts and
reduced expression of MHC class II molecules [4]. We
therefore tested our Swedish MG patients and controls
for association with this SNP, revealing that no signifi-
cant difference in the allelic frequencies of the SNP
exists between patients and controls and among
patients when stratified by clinical subgroups of the
disease.
Our Swedish control material differed from the Swedish
control material presented by Swanberg et. al. [4] with a
significantly higher frequency of the minor (G) allele
(0.266 and 0.216, respectively, p < 10-5). In order to
exclude association of MG with rs3087456, given the large
variation in control allele frequencies, we also compared
MG allele frequencies to this control material. However,
Table 2 Summary of published CIITA SNP rs3087456 association studies in autoimmune disorders
Study Year Population Disease Patients/Controls Association
Swanberg, et. al. [4] 2005 Sweden RA 1262/2506 p = 0.012
Swanberg, et. al. [4] 2005 Sweden MS 520/2506 p = 0.028
Swanberg, et. al. [4] 2005 Sweden MI 376/2506 p = 0.014
Koizuma et. al. [20] 2005 Japan SLE 100/100 Not significant
Yazdani-Biuki et. al. [21] 2006 Austria RA 362/1709 Not significant
Orozco et. al. [12] 2006 Spain RA 748/676 p = 0.01a
Orozco et. al. [12] 2006 Sweden RA 278/478 Not significant
Orozco et. al. [12] 2006 Argentina RA 287/287 Not significant
Akkad et. al. [22] 2006 Germany RA 319/463 Not significant
Akkad et. al. [22] 2006 Germany MS 646/463 Not significant
Akkad et. al. [22] 2006 Germany WGb 178/463 Not significant
Eyre et. al. [23] 2006 UK RA 1401/2475 Not significant
Lindholm et. al. [24] 2006 Finland/Sweden MI 1222/2345 Not significant
Ghaderi et. al. [16] 2006 Italy AADc 128/406 p = 0.003
O’Doherty et. al. [25] 2007 Ireland RA 293/316 Not significant
O’Doherty et. al. [25] 2007 Ireland MS 440/316 Not significant
O’Doherty et. al. [25] 2007 Ireland JIAd 74/316 Not significant
Linga-Reddy et. al. [17] 2007 Sweden SLE 334/478 Not significant
Martinez et. al. [26] 2007 Spain RA 350/519 Not significant
Martinez et. al. [26] 2007 Spain MS 396/519 Not significant
Martinez et. al. [26] 2007 Spain IBSe 663/519 Not significant
Iikuni et. al. [13] 2007 Japan RA 1121/450 p = 0.003f
Harrison et. al. [27] 2007 UK RA 733/613 Not significant
Sánchez et. al. [28] 2008 SLE SLE 394/514 Not significant
Pan-Hammarström, et. al. [29] 2008 Sweden CVIDg 97/1826 Not significant
Pan-Hammarström, et. al. [29] 2008 Sweden IgADh 249/1826 Not significant
Skinningsrud, et. al. [15] 2008 Norway AADc 332/1029 p = 0.044i
Dema et. al. [30] 2009 Spain CDj 607/794 Not significant
Bronson, et. al. [19] 2010 USA/UK MS 1320/1363 Not significant





fAssociation with the major (A) rather than the minor allele of rs3087456.
gCommon variable immunodeficiency.
hIgA deficiency.
iUncorrected p-value in a study of 139 SNPs.
jCeliac disease.
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the MG group did not show a statistically significant asso-
ciation, nor did any subgroup of MG (Table 1).
Although the initial study on rs3087456 in autoim-
mune/inflammatory disorders showed a clear association
with the minor (G) allele, subsequent studies on a vari-
ety of similar disorders have been inconsistent and for
the most part have shown a lack of association. Of 17
replication studies using patients from 26 different dis-
ease cohorts (Table 2), only four have found an associa-
tion between rs3087456 and a disorder. In the case of
RA, eight replication studies have been conducted in 10
different populations, of which only two [12,13] found
an association with rs3087456. In one of the latter,
Iikuni et. al. found that although the allele frequencies
in controls were similar to those in Sweden, the major
(A) allele was associated with an increased risk of RA in
a Japanese patient cohort (p = 0.003). This result runs
contrary to the increased risk of the minor (G) allele
reported in a Swedish population [4] and brings the pro-
posed genetic mechanism associated with the minor
allele into question. A meta-analysis of the 10 RA data
sets consisting of 6861 patients and 9270 controls also
determined that neither the G allele (p = 0.70) nor the
GG genotype (p = 0.16) are associated to the disease
[14].
In the 16 data sets from studies which have examined
the association of the SNP with other autoimmune/
inflammatory disorders than RA, only two have reported
a positive association to the SNP, both with autoim-
mune Addison’s disease [15,16]. In the first study, the
p-value (p = 0.044) was not corrected for multiple test-
ing in a study of 139 SNPs, drawing the association into
question. One replication study in patients with myocar-
dial infarction as well as four in multiple sclerosis in dif-
ferent populations did not find any association with
rs3087456. Furthermore, a Swedish study, which found
no association of the SNP with SLE, had a MAF of
0.253, in 956 controls, similar to that in our controls
(p = 0.41), and the authors concluded that the differ-
ences in allele frequencies between their controls and
those of Swanberg et. al. could not be explained by
population substructure [17].
Although there is evidence of potential interaction
between SNPs in CIITA [18] and HLA alleles [19] in
autoimmunity, the promoter SNP rs3087456 alone
appears to predispose neither to myasthenia gravis nor
to autoimmunity in general. A further investigation of
interacting factors contributing to altered MHC class II
expression in autoimmune disorders is warranted.
Conclusions
The lack of allelic association of the CIITA SNP
-168A®G (rs3087456) with MG casts further doubt on
the presumed role of this particular SNP in autoimmune
disorders. In the case of single gene association, results
should be replicated, even in the same population, to
confirm their validity. This study also illustrates the
importance of large, homogeneous sample sizes, particu-
larly for controls, in order to avoid publication bias.
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